On Wednesday, New York-headquartered Focus Financial Partners announced plans to make Cardinal Point, which it acquired in ...

The last round in 2021 valued the healthcare technology firm at $3.2 billion, more than doubling its valuation from $1.3 ...

Defiant is a new early stage VC firm focused on B2B SaaS and fintech coming out of stealth Thursday. Joseph Pizzolato ...

Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, today announced a $62 million Series A financing. The financing was led by founding investor Versant Ventures ...

Hengdian Group Capital (HgC) and Apeloa Pharmaceutical (subsidiaries of Hengdian Group) will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 13-16, ...

The marquee investors in the asset-rich subsidiaries of Reliance Industries (RIL) -- Jio Platforms Ltd (JPL) and Reliance ...

Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, announced a multi-target collaboration with Novartis to identify and develop potentially first-in-class ...

About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...

Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...